Emerging Agents in the Management of Schizophrenia
neuroscienceCME WebcastPremiere Date: Wednesday, February 10, 2016
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 10, 2017
Note: Credit Is No Longer Available
|Jeffrey A. Lieberman, MD
President, American Psyichiatric Association
Lawrence C. Kolb Professor and Chairman, Department of Psychiatry
College of Physicians and Surgeons, Columbia University
Director, New York State Psychiatric Institute
Psychiatrist-in-Chief at New York Presbyterian Hospital & Columbia University Medical Center
New York, NY
This video is a replay of a plenary session from the 8th Annual Chair Summit Master Class for Neuroscience Professional Development held in Miami Florida on September 24-26, 2015.
At the end of this CE activity, participants should be able to:
- Describe the emerging therapies for the treatment of schizophrenia.
This activity is supported by an educational grant from Allergan, Inc.
Physicians, physician assistants, nurse practitioners, and other nonphysician health care professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Credit (Physicians): CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr Lieberman has the following disclosures:
Research/Grants: Alkermes; BioMarin Pharmaceutical Inc.; EnVivo Pharmaceuticals, Inc./FORUM Pharmaceuticals Inc.; Novartis Corporation; Sunovion Pharmaceuticals Inc.
Consultant: Clintara; Intracellular Therapies, Inc.; Pear Therapeutics
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).